TY - JOUR

T1 - Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy

T2 - results of a randomized trial

AU - Hindley, Andrew

AU - Zain, Zakiyah

AU - Wood, Lisa

AU - Whitehead, Anne

AU - Sanneh, Alison

AU - Barber, David

AU - Hornsby, Ruth

PY - 2014/11/15

Y1 - 2014/11/15

N2 - PurposeWe wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study (Boström et al, Radiother Oncol 2001;59:257-265).Methods and MaterialsThe study was a double-blind comparison of MF with D (Diprobase), administered daily from the start of radiation therapy for 5 weeks in patients receiving breast radiation therapy, 40 Gy in 2.67-Gy fractions daily over 3 weeks. The primary endpoint was mean modified Radiation Therapy Oncology Group (RTOG) score.ResultsMean RTOG scores were significantly less for MF than for D (P=.046). Maximum RTOG and mean erythema scores were significantly less for MF than for D (P=.018 and P=.012, respectively). The Dermatology Life Quality Index (DLQI) score was significantly less for MF than for D at weeks 4 and 5 when corrected for Hospital Anxiety and Depression (HAD) questionnaire scores.ConclusionsMF cream significantly reduces radiation dermatitis when applied to the breast during and after radiation therapy. For the first time, we have shown a significantly beneficial effect on quality of life using a validated instrument (DLQI), for a topical steroid cream. We believe that application of this cream should be the standard of care where radiation dermatitis is expected.SummaryIn a randomized trial of patients receiving radiation therapy to the breast or chest wall, mometasone furoate cream, when applied from the start of radiation therapy for 5 weeks, was shown to significantly reduce mean Radiation Therapy Oncology Group skin toxicity scores and objective erythema measurements and to significantly reduce impairment of quality of life, using the Dermatology Life Quality Index.

AB - PurposeWe wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study (Boström et al, Radiother Oncol 2001;59:257-265).Methods and MaterialsThe study was a double-blind comparison of MF with D (Diprobase), administered daily from the start of radiation therapy for 5 weeks in patients receiving breast radiation therapy, 40 Gy in 2.67-Gy fractions daily over 3 weeks. The primary endpoint was mean modified Radiation Therapy Oncology Group (RTOG) score.ResultsMean RTOG scores were significantly less for MF than for D (P=.046). Maximum RTOG and mean erythema scores were significantly less for MF than for D (P=.018 and P=.012, respectively). The Dermatology Life Quality Index (DLQI) score was significantly less for MF than for D at weeks 4 and 5 when corrected for Hospital Anxiety and Depression (HAD) questionnaire scores.ConclusionsMF cream significantly reduces radiation dermatitis when applied to the breast during and after radiation therapy. For the first time, we have shown a significantly beneficial effect on quality of life using a validated instrument (DLQI), for a topical steroid cream. We believe that application of this cream should be the standard of care where radiation dermatitis is expected.SummaryIn a randomized trial of patients receiving radiation therapy to the breast or chest wall, mometasone furoate cream, when applied from the start of radiation therapy for 5 weeks, was shown to significantly reduce mean Radiation Therapy Oncology Group skin toxicity scores and objective erythema measurements and to significantly reduce impairment of quality of life, using the Dermatology Life Quality Index.

U2 - 10.1016/j.ijrobp.2014.06.033

DO - 10.1016/j.ijrobp.2014.06.033

M3 - Journal article

VL - 90

SP - 748

EP - 755

JO - International Journal of Radiation Oncology - Biology - Physics

JF - International Journal of Radiation Oncology - Biology - Physics

SN - 0360-3016

IS - 4

ER -